These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
895 related articles for article (PubMed ID: 18397336)
1. A comparative in-vitro evaluation of resistance selection after exposure to teicoplanin, vancomycin, linezolid and quinupristin-dalfopristin in Staphylococcus aureus and Enterococcus spp. Drago L; Nicola L; De Vecchi E Clin Microbiol Infect; 2008 Jun; 14(6):608-11. PubMed ID: 18397336 [TBL] [Abstract][Full Text] [Related]
2. Linezolid and quinupristin/dalfopristin resistance in vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus prior to clinical use in Turkey. Baysallar M; Kilic A; Aydogan H; Cilli F; Doganci L Int J Antimicrob Agents; 2004 May; 23(5):510-2. PubMed ID: 15120733 [TBL] [Abstract][Full Text] [Related]
3. In vitro activity of linezolid & quinupristin/dalfopristin against Gram-positive cocci. Tünger A; Aydemir S; Uluer S; Cilli F Indian J Med Res; 2004 Dec; 120(6):546-52. PubMed ID: 15654141 [TBL] [Abstract][Full Text] [Related]
4. In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin. Anastasiou DM; Thorne GM; Luperchio SA; Alder JD Int J Antimicrob Agents; 2006 Nov; 28(5):385-8. PubMed ID: 17046205 [TBL] [Abstract][Full Text] [Related]
5. In vitro analysis of resistance selection by linezolid in vancomycin-susceptible and -resistant Enterococcus faecalis and Enterococcus faecium. Allen GP; Bierman BC Int J Antimicrob Agents; 2009 Jul; 34(1):21-4. PubMed ID: 19243921 [TBL] [Abstract][Full Text] [Related]
6. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium. Jevitt LA; Smith AJ; Williams PP; Raney PM; McGowan JE; Tenover FC Microb Drug Resist; 2003; 9(4):389-93. PubMed ID: 15000746 [TBL] [Abstract][Full Text] [Related]
7. Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan. Huang YT; Liao CH; Teng LJ; Hsueh PR Clin Microbiol Infect; 2008 Feb; 14(2):124-9. PubMed ID: 18076671 [TBL] [Abstract][Full Text] [Related]
8. Susceptibility of methicillin-resistant Staphylococcus aureus to vancomycin, teicoplanin, linezolid, pristinamycin and other antibiotics. Samra Z; Ofer O; Shmuely H Isr Med Assoc J; 2005 Mar; 7(3):148-50. PubMed ID: 15792257 [TBL] [Abstract][Full Text] [Related]
9. LEADER surveillance program results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from the United States (50 medical centers). Jones RN; Fritsche TR; Sader HS; Ross JE Diagn Microbiol Infect Dis; 2007 Nov; 59(3):309-17. PubMed ID: 17720350 [TBL] [Abstract][Full Text] [Related]
10. In vitro activity of the oxazolidinone RWJ-416457 against linezolid-resistant and -susceptible staphylococci and enterococci. Livermore DM; Warner M; Mushtaq S; North S; Woodford N Antimicrob Agents Chemother; 2007 Mar; 51(3):1112-4. PubMed ID: 17210773 [TBL] [Abstract][Full Text] [Related]
11. Bactericidal activity of daptomycin, vancomycin, teicoplanin and linezolid against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium using human peak free serum drug concentrations. Brauers J; Kresken M; Menke A; Orland A; Weiher H; Morrissey I Int J Antimicrob Agents; 2007 Mar; 29(3):322-5. PubMed ID: 17204403 [TBL] [Abstract][Full Text] [Related]
12. Susceptibility to daptomycin, quinupristin-dalfopristin and linezolid and some other antibiotics in clinical isolates of methicillin resistant and methicillin sensitive S.aureus from the Oslo area. Jørgen B; Merckoll P; Melby KK Scand J Infect Dis; 2007; 39(11-12):1059-62. PubMed ID: 17852934 [TBL] [Abstract][Full Text] [Related]
13. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center. Smith PF; Booker BM; Ogundele AB; Kelchin P Diagn Microbiol Infect Dis; 2005 Jul; 52(3):255-9. PubMed ID: 15935606 [TBL] [Abstract][Full Text] [Related]
14. [Sensitivity of methicillin resistant staphylococci to linezolid and some other antimicrobial agents]. Ertek M; Yazgi H; Aktaş E; Ayyildiz A; Parlak M Mikrobiyol Bul; 2003 Oct; 37(4):235-40. PubMed ID: 14748259 [TBL] [Abstract][Full Text] [Related]
15. In vitro activity of linezolid, quinupristin-dalfopristin, vancomycin, teicoplanin, moxifloxacin and mupirocin against methicillin-resistant Staphylococcus aureus: comparative evaluation by the E test and a broth microdilution method. Abb J Diagn Microbiol Infect Dis; 2002 Aug; 43(4):319-21. PubMed ID: 12151194 [TBL] [Abstract][Full Text] [Related]
16. Comparative in vitro activity of vancomycin and other antimicrobial agents against methicillin-resistant staphylococcus aureus and enterococcus faecium in the Tohoku district of Japan. Lutfor AB; Kikuchi T; Tokue Y; Takahashi H; Shoji S; Fujimura S; Nukiwa T; Watanabe A Chemotherapy; 1998; 44(5):318-23. PubMed ID: 9732146 [TBL] [Abstract][Full Text] [Related]
17. Clinical-use-associated decrease in susceptibility of vancomycin-resistant Enterococcus faecium to linezolid: a comparison with quinupristin-dalfopristin. Raad II; Hanna HA; Hachem RY; Dvorak T; Arbuckle RB; Chaiban G; Rice LB Antimicrob Agents Chemother; 2004 Sep; 48(9):3583-5. PubMed ID: 15328133 [TBL] [Abstract][Full Text] [Related]
18. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269 [TBL] [Abstract][Full Text] [Related]
19. Intra-hospital dissemination of quinupristin/dalfopristin- and vancomycin-resistant Enterococcus faecium in a paediatric ward of a German hospital. Werner G; Klare I; Spencker FB; Witte W J Antimicrob Chemother; 2003 Jul; 52(1):113-5. PubMed ID: 12805253 [TBL] [Abstract][Full Text] [Related]